Malaria transmission-blocking vaccines – ARTES and Burnet announced a development project

ARTES Biotech­nol­o­gy and Bur­net Insti­tute have joined forces to devel­op a new type of malar­ia vac­cine in a project fund­ed by the PATH Malar­ia Vac­cine Ini­tia­tive (MVI).

The project will use excit­ing nov­el tech­nol­o­gy devel­oped at the Bur­net Insti­tute. ARTES holds the inter­na­tion­al patent rights and adapt­ed the plat­form to vac­cine pro­duc­tion (known as the Metavax® plat­form).

Puri­fied vac­cine anti­gens (Pfs25 and Pfs230) will be pro­duced as virus-like par­ti­cles (VLPs, a type of nano-par­ti­cle) for test­ing in lab­o­ra­to­ry stud­ies. The VLPs will be tak­en up by immune cells to prime and pre­pare the immune sys­tem to fight malar­ia.

The project will focus on strate­gies to pro­duce vac­cines that can block the trans­mis­sion of malar­ia infec­tion from mos­qui­toes to peo­ple, as part of a pro­gram fund­ed by MVI.

http://www.burnet.edu.au/